Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.76 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.76 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.76 |
| ▸ | TNF | P01375 | 1/20 | 0.76 |
| ▸ | IL1B | P01584 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283314 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282492 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30001891 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283184 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22737352 | 0.87 | CRBN (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 0.86 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21996834 | 0.86 | CRBN (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| Avadomide SCHEMBL282749 | 0.86 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| Avadomide SCHEMBL634577 | 0.86 | CRBN (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25347071 | 0.86 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| EP-4480948-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | disclosed |
| CN-116589445-A | Compound based on quinazoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | CRBN, CLN6, CDR2 | DDB1 2501/4885CRBN 1/4885IKZF3 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.